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Objective To evaluate intravenous (IV) detomidine with methadone in horses to identify a 25 
combination which provides sedation and antinociception without adverse effects.  26 
Study design Randomized, placebo-controlled, blinded, crossover. 27 
Animals Eight adult healthy horses aged (mean ± standard deviation) 7 ± 2 years and 372 ± 28 
27 kg. 29 
Methods Six treatments were administered IV: saline (SAL); detomidine (5 µg kg-1; DET); 30 
methadone (0.2 mg kg-1; MET) alone or combined with detomidine [2.5 (MLD), 5 (MMD) or 31 
10 (MHD) µg kg-1]. Thermal, mechanical and electrical nociceptive thresholds (NT) were 32 
measured, and sedation, head height above ground (HHAG), cardiopulmonary variables and 33 
intestinal motility were evaluated at 5, 15, 30, 45, 60, 75, 90, 120, 180 minutes. Normal data 34 
were analyzed by mixed-model ANOVA and non-normal by Kruskal-Wallis (p < 0.05). 35 
Results Nociceptive thresholds in horses administered methadone with the higher doses of 36 
detomidine (MMD, MHD) were increased above baseline to a greater degree and for longer 37 
duration (MMD: 15-30 minutes, MHD: 30-60 minutes) than in horses administered low dose 38 
with methadone or detomidine alone (MLD, DET: 5-15 minutes). No increases in NT were 39 
recorded in SAL or MET. Compared with baseline, HHAG was lower for 30 minutes in 40 
MMD and DET, and for 45 minutes in MHD. No significant sedation was observed in SAL, 41 
MET or MLD. Intestinal motility was reduced for 75 minutes in MHD and for 30 minutes in 42 
all other treatments. 43 
Conclusions Methadone (0.2 mg kg-1) potentiated the antinociception produced by 44 
detomidine (5 µg kg-1), with minimal sedative effects.  45 
Clinical relevance Detomidine (5 µg kg-1) with methadone (0.2 mg kg-1) produced 46 
antinociception without the adverse effects of higher doses of detomidine. 47 
 48 
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Introduction 52 
It is common practice to administer drug combinations for chemical restraint of standing 53 
horses, avoiding the potential complications and costs of general anaesthesia. The α2-agonist 54 
detomidine has been extensively used to produce sedation and analgesia. However, adverse 55 
effects associated with detomidine administration, especially occurring after intravenous (IV) 56 
bolus administration, include ataxia, bradycardia, arrhythmias, increased systemic vascular 57 
resistance and reduction in cardiac output, respiratory rate (fR), arterial oxygen tension and 58 
intestinal motility (Yamashita et al. 2000; Daunt & Steffey 2002; Valverde 2010). 59 
 Combinations of an α2-agonist with an opioid provide synergistic analgesic effects 60 
with predictable sedation (Marly et al. 2014; Oliveira et al. 2014; Taylor et al. 2014; Lopes et 61 
al. 2016), while potentially reducing adverse effects. Opioids play an important role in 62 
analgesia in other species, however, their use in horses is controversial owing to the potential 63 
for excitement and intestinal hypomotility, especially when administered IV (Bennett & 64 
Steffey 2002; Clutton 2010; Schauvliege 2014). Methadone, a synthetic µ-agonist opioid with 65 
similar properties to morphine, also provides analgesia by antagonizing N-methyl-D-aspartate 66 
(NMDA) receptors and has delta opioid receptor activity (Pollock et al. 2011).  67 
Methadone (0.5 mg kg-1) administered IV alone increased spontaneous locomotor 68 
activity and impaired coordination in horses (Combie et al. 1979; Oliveira et al. 2014), and 69 
the duration of thermal antinociception was short at 30 minutes (Oliveira et al. 2014). Lower 70 
doses (0.2 mg kg-1) administered IV have resulted in less adverse behavioral effect but 71 
provided insufficient antinociception (Pippi & Lumb 1979; Oliveira et al. 2014). More recent 72 
studies reported that methadone (0.2 mg kg-1) did not produce antinociception when 73 
administered alone, but potentiated antinociception induced by detomidine (10 µg kg-1) 74 
(Oliveira et al. 2014; Lopes et al. 2016). No adverse effects were reported after 75 
administration of methadone (0.15 mg kg-1) IV, but antinociception was not reported (Linardi 76 
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et al. 2012). These studies suggest that further evaluation of lower doses of methadone in 77 
combination with detomidine in horses may be worthwhile.  78 
Our hypothesis was that the combination of low (2.5 µg kg-1) and medium (5 µg kg-1) 79 
doses of detomidine with methadone (0.2 mg kg-1) would result in sedation and analgesia 80 
with less adverse effects when compared with the administration of each drug alone. The aim 81 
of the study was to identify a combination resulting in antinociception with minimal adverse 82 
effects by evaluating the sedative, antinociceptive and potential side effects of some 83 
combinations of detomidine and methadone. 84 
 85 
Materials and methods 86 
The study was designed as a prospective, randomized, placebo-controlled, observer blinded 87 
crossover, with a washout period of ≥1 week between treatments. It was approved by the 88 
Institutional Ethical Committee for the Use of Animals in Research of the Faculty of 89 
Veterinary Medicine and Animal Science of the State of São Paulo University (UNESP), 90 
Botucatu (EC no. 08/2015). 91 
 92 
Animals 93 
Eight healthy adult cross-bred horses (four castrated males, four females), aged [mean ± 94 
standard deviation (SD) (range)] 7 ± 2 years (3-9 years), weighing 372 ± 27 kg (325-420 kg) 95 
were studied. The animals were kept at grass and brought to covered pens with outdoor 96 
access at least 24 hours before each experiment. Commercial horse feed, hay and ad libitum 97 
water were provided. The horses were considered healthy based upon physical examination 98 
and laboratory investigations performed 1-2 weeks before the study started. No sedatives or 99 
analgesics were administered for at least 1 month before the beginning of the study. 100 
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 The sample size was estimated using OpenEpi Software (www.openepi.com) based on 101 
the results of a pilot study with three horses and from previous data (Oliveira et al. 2014; 102 
Lopes et al. 2016). The expected mean differences between the antinociceptive variables in 103 
the different treatments were assessed. A test power of 80% and a significance level of 5% 104 
were employed. 105 
 106 
Study design 107 
The horses were weighed on the day of each experiment and fly repellent was applied to the 108 
skin. The hair over both jugular veins was clipped for catheter placement. After skin 109 
disinfection, 1 mL of 2% lidocaine (Xylestesin 2% ; Cristália Produtos Químicos 110 
Farmacêuticos Ltda, SP, Brazil) was injected subcutaneously and two 14 gauge catheters 111 
were placed at each site, in the direction of the blood flow. The one in the right jugular vein 112 
was used for drug administration (14 gauge, 48 mm BD Angiocath; Becton Dickinson Ind., 113 
MG, Brazil) and in the left (14 gauge, 70 mm, Delta Med Srl, Italy) for blood sampling for 114 
pharmacokinetic analysis (results reported elsewhere). Hair was clipped over the dorsal 115 
aspects of both metacarpi for the thermal and mechanical devices, and immediately proximal 116 
to the coronary band of the left thoracic limb for the electrical electrodes. To obtain a good 117 
contact for the electrodes and to reduce resistance, the clipped coronary skin was washed 118 
with water and degreased with chlorhexidine containing surfactants (RIOHEX 2% ; Industria 119 
Farmaceutica Rioquimica Ltda, SP, Brazil). This process was repeated twice. 120 
After that, the horse was brought to the experimental room (6 m2, without windows), 121 
previously sprayed with fly repellent, and allowed 30 minutes for familiarization. A blood 122 
pressure cuff [DURA-CUF CRITIKON (12–19 and 17–25 cm); GE Healthcare, Finland] was 123 
placed at the base of the tail, to measure heart rate (HR) and systolic arterial blood pressure 124 
(SAP) with a noninvasive Doppler (Model 812; Parks Medical Electronics, Inc., OR, USA). 125 
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The prepared area at the left coronary band was twice cleaned with alcohol (Álcool 96; 126 
Farmácia Santa Cruz, SP, Brazil) and dried before attaching two adhesive electrodes 127 
(2223BRQ; 3M do Brasil Ltda, SP, Brazil) 8 cm apart, secured with four adhesive wrap strips 128 
around the hoof. The thermal (WTT2; Topcat Metrology Ltd, UK) and mechanical (WMT1; 129 
Topcat Metrology Ltd) control units (Topcat Metrology Ltd) were attached with Velcro onto 130 
a commercial blanket (Topcat Metrology Ltd) on the horse’s back. The units were remotely 131 
controlled by infrared signals. Temperature and force were recorded in degrees Celsius (°C) 132 
and newtons (N), respectively. Finally, the thermal sensor on the right clipped metacarpus 133 
and mechanical pin on the left were placed and connected to the control units.  134 
Six treatments were randomly assigned using Microsoft Excel: saline (Cloreto de 135 
sódio 0.9%; Fresenius Kabi, SP, Brazil; treatment SAL), detomidine (5 µg kg-1; Eqdomin, 10 136 
mg mL-1; Ourofino Saúde Animal, SP, Brazil; treatment DET), methadone (0.2 mg kg-1; 137 
Mytedom 10 mg mL-1, Cristália Produtos Químicos Farmacêuticos Ltda, SP, Brazil; 138 
treatment MET), and methadone at the same dose combined with detomidine (2.5 µg kg-1; 139 
treatment MLD), detomidine (5 µg kg-1; treatment MMD) and detomidine (10 µg kg-1; 140 
treatment MHD). The final volume was adjusted to 10 mL by adding saline and administered 141 
IV by hand at T0 over 10 seconds. 142 
Sedation and responses to antinociceptive stimuli were evaluated in triplicate at 143 
baseline (T0) before and at 5, 15, 30, 45, 60, 75, 90, 120 and 180 minutes after drug 144 
administration. Intestinal motility was scored at the same time points starting at 15 minutes.  145 
 146 
Degree and quality of sedation  147 
Sedation was evaluated using the height of the head above the ground (HHAG) by measuring 148 
the level of the lower lip against a scale on the wall (Ringer et al. 2012; Marly et al. 2014). 149 
Quality of sedation was scored first by evaluating the degree of ataxia and second by 150 
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responses to tactile and audiovisual stimulation, always in the same order. The scoring 151 
system was a numerical rating scale (NRS) ranging from 0 to 3 for ataxia (0 no ataxia, 3 152 
maximal ataxia) and responses to audiovisual stimuli (0 no response, 3 maximal response) 153 
(Appendix A). A subjective visual analogue scale (VAS) was assigned consisting of a 10 cm 154 
line where 0 cm represented no sedation or ataxia and 10 cm represented maximal sedation 155 
and/or maximal ataxia. All the sedation variables were always evaluated by the main 156 
investigator (MGM) unaware of the treatment.  157 
 158 
Cardiopulmonary variables 159 
SAP was corrected according to the height difference between the cuff and shoulder joint, the 160 
latter location representing the level of the right atrium of the heart. The fR was measured by 161 
observation of chest movements over 30 seconds. 162 
 163 
Nociceptive threshold testing 164 
Nociceptive stimuli were applied at each time point immediately after sedation was scored 165 
and cardiopulmonary variables had been recorded. Stimuli were always applied in the same 166 
order; first electrical, followed by thermal and mechanical stimulation. Aversive responses 167 
were recorded when the horse lifted its foot, pawed the ground, stamped, flexed the limb or 168 
walked to avoid the stimulus (Luna et al. 2015). The stimulus was immediately withdrawn at 169 
this end point and the value in volts (V), °C and N at threshold recorded. If cut-out was 170 
reached, this value was recorded as the threshold.  171 
 172 
Electrical threshold testing 173 
The resistance between electrodes was measured using a digital multimeter (ET 1100 ; 174 
Minipa do Brasil Ltda, SP, Brazil) to confirm it was below 3 kΩ. The electrodes were 175 
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connected to an electrical stimulator (Grass S-48; Astro-Med, Inc., RI, USA) adjusted to 176 
deliver pulsatile current square waves of 10 ms at 10 Hz. The voltage started at 1 V, then was 177 
increased by 1 V every 5 seconds. Stimulation was stopped immediately when an avoidance 178 
response was observed or the voltage reached 20 V.  179 
 180 
Thermal threshold testing 181 
A thermal probe with a heating element encased in an 8 mm long brass tube (internal 182 
diameter 2.4 mm and external diameter 3.2 mm) (probe 3; Dixon et al. 2016) was placed on 183 
the clipped area of the right metacarpus and attached with an elasticated band secured by 184 
Velcro. The probe includes a heater and a temperature sensor and is connected to the thermal 185 
control unit. At least 5 minutes were allowed for equilibration with body temperature. After 186 
recording skin temperature, the ramped stimulus was applied, heating at 0.8 °C second-1 until 187 
a positive response was observed or the cut-out at 60 °C was reached (Luna et al. 2015; 188 
Lopes et al. 2016). After each stimulus, the probe was moved 1-2 cm proximally on the limb 189 
to avoid focal tissue damage. 190 
 191 
Mechanical threshold testing 192 
A pneumatic actuator containing a 1 mm round-ended pin was secured with a brushing boot 193 
on the left clipped metacarpal area, held against the leg with an elasticated band secured with 194 
Velcro and connected to the control unit with non-distensible tubing (Taylor et al. 2016). The 195 
automatic control system increased the force of the pin pressing on the skin surface at 0.8 N 196 
second-1. The stimulus was stopped when an aversive response was observed or the cut-out 197 
value of 20 N reached.  198 
 199 
Abdominal auscultation 200 
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Intestinal sounds were assessed by auscultation over one minute in each of the four 201 
abdominal quadrants: right dorsal, right ventral, left dorsal and left ventral. The total motility 202 
score was the sum of the scores from each quadrant (Boscan et al. 2006) (Appendix B).   203 
 204 
Statistical analysis 205 
For each variable, normality was assessed by the Shapiro-Wilk test and graphical analysis. 206 
Effects of time and treatment were analyzed with a mixed-model analysis of variance 207 
(ANOVA) followed by Tukey´s test for HHAG, cardiopulmonary variables, thermal stimulus 208 
and intestinal motility (mean ± SD). Data from electrical and mechanical stimuli were not 209 
normally distributed. Thus, logarithmic transformation was performed, and these data are 210 
presented as geometric mean (back-transformed bounds of the 95% confidence interval). 211 
Different covariance structures were tested. Data for ataxia, responses to tactile and 212 
audiovisual stimuli and VAS, non-normally distributed, were analyzed by Kruskal-Wallis 213 
with Dunn´s tests and are presented as median (range). Significance level was set at 0.05. 214 
 215 
Results 216 
The HHAG was lower than baseline (sedation was greater) after DET (66 ± 26 versus 98 ± 217 
10 cm) and MMD (77 ± 19 versus 99 ± 3 cm) for 30 minutes and after MHD (68 ± 26 versus 218 
99 ± 9 cm) for 45 minutes (Fig. 1). Comparing treatments, HHAG with DET was lower than 219 
SAL, MET and MLD for 30 minutes. The HHAG with MMD was lower than SAL and MLD 220 
for 15 minutes and MET for 30 minutes, respectively. The HHAG with MHD was lower than 221 
SAL, MET, MLD for 45 minutes and between 15 and 45 compared with MMD. There were 222 
no differences between DET and MHD. 223 
Visual analogue scores were significantly higher than baseline for 30 minutes only in 224 
treatments DET, MMD and MHD (Table 1). Comparing treatments, MHD scores were not 225 
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different from MMD or DET at any time point, but were higher than MLD for 45 minutes, 226 
and higher than SAL and MET for 60 minutes (Table 1). Scores in MMD were not different 227 
from DET or MLD at any time point, but were higher than SAL and MET for 30 minutes. 228 
The ataxia scores were higher than baseline [0 (0 – 0)] with DET [1 (0 – 1)], MMD [1 229 
(0 – 2)] and MHD [1 (0 – 3)] up to 15 minutes (p < 0.05). Comparing treatments, ataxia was 230 
more pronounced with MHD [1 (0 – 3)] than with SAL [0 (0 – 0)] and MET [0 (0 – 0)] for 30 231 
minutes (p < 0.05). Ataxia scores with MHD [2 (1 – 3)] were also higher than MLD [1 (0 – 232 
3)] at 5 minutes (p < 0.05).  233 
Scores for responses to tactile stimuli were lower than baseline [3 (2 – 3)] with MMD 234 
[1.5 (0 – 2)] for 5 minutes and up to 30 minutes in MHD [1 (0 – 2)] (p < 0.05). Comparing 235 
treatments, scores were lower with MHD [2 (0 – 3)] than SAL [3 (3 – 3)] and MET [3 (3 – 236 
3)] up to 45 minutes, lower than MLD at 15 [[0 (0 – 1)] versus [3 (1 – 3)]] and at 30 minutes 237 
[[1 (0 – 2)] versus [3 (1 – 3)] and lower than DET at 15 [[0 (0 – 1)] versus [2.5 (1 – 3)]] and 238 
45 minutes [[2 (0 – 3)] versus [3 (3 – 3)]] (p < 0.05). Scores were also lower with MMD [1.5 239 
(0 – 2)] than SAL [3 (3 – 3)] and MET [3 (2 – 3)] at 5 minutes (p < 0.05).  240 
Scores of responses to audiovisual stimuli were lower than baseline [1 (1 – 2)] for 15 241 
minutes in MHD [0 (0 – 1)] (p < 0.05). Comparing treatments, scores were lower with MHD 242 
[0 (0 – 1)] than SAL [1 (1 – 2)] and MET [1 (1 – 2)] for up to 15 minutes and lower than 243 
MLD at 5 minutes [0 (0 – 0)] versus [1 (1 – 2)] (p < 0.05).  244 
HR were not significantly changed from baseline within all treatments (Table 2). 245 
Statistically significant changes in SAP and fR were recorded in some treatments (Table 2).  246 
Electrical thresholds in treatments MHD, MMD, MLD and DET were significantly 247 
higher than baseline for 30, 15, 5 and 15 minutes, respectively (Table 3). Comparing 248 
treatments, MHD thresholds were higher than MMD at 15 and 30 minutes only, but were 249 
higher than DET, MLD and SAL for 30 minutes and MET for 45 minutes. After MMD, 250 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
thresholds were higher than MET and SAL only for 15 minutes. Thresholds at, and after 60 251 
minutes were not different from baseline and between treatments.  252 
Thermal thresholds in treatments MHD, MMD, MLD and DET were significantly 253 
higher than baseline for 45, 30, 15 and 15 minutes, respectively (Table 3). Comparing 254 
treatments, MHD thresholds were higher than MMD only at 30 minutes, higher than MLD 255 
and DET from 15-45 minutes and higher than SAL and MET at all time points up to 45 256 
minutes. Thermal thresholds in MMD were higher than DET only at 30 minutes, and higher 257 
than SAL and MET for 30 minutes. Thresholds in MLD and DET were higher than MET for 258 
5 minutes and SAL for 15 minutes. Thresholds at, and after 60 minutes were not different 259 
from baseline and between treatments. 260 
Mechanical thresholds in MHD, MMD, MLD and DET were significantly higher than 261 
baseline for 60, 30, 15 and 5 minutes, respectively (Table 3). Comparing treatments, MHD 262 
thresholds were higher than MLD only at 30 minutes, higher than DET at 15-60 minutes, 263 
higher than MET for 45 minutes, and higher than SAL for up to 60 minutes. Mechanical 264 
thresholds in MMD were higher than DET only at 15 minutes, and higher than MET and 265 
SAL for 15 minutes. Thresholds at, and after 75 minutes were not different from baseline and 266 
between treatments.  267 
Intestinal motility was below baseline in MET, DET, MLD and MMD for 30 minutes 268 
and up to 75 minutes in MHD (Fig. 2). Comparing treatments, MET, DET, MMD and MLD 269 
were lower than SAL for 30 minutes, and MHD was lower for 60 minutes. MHD was lower 270 
than MET and MMD for 30 minutes and lower than MLD and DET for 45 minutes.  271 
 Methadone alone (MET) resulted in mild behavioral effects in the first 5-15 minutes: 272 
two horses were restless, two flicked their lower lips, one made minor attempts to move and 273 
one was sedated. No adverse effects were observed in the remaining two horses. No abnormal 274 
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behavioral effects were observed after any other treatments except in MLD where one horse 275 
flicked the lower lips and one briefly became very alert to the environment. 276 
One horse became deeply sedated in response to both drugs, either alone or in 277 
combination. In this horse only, some superficial skin lesions became evident a few hours 278 
after application of thermal stimuli in the third treatment, when thresholds close to the cut-out 279 
temperature were reached. The lesions started as edematous wheals mimicking the footprint 280 
of the probe. The outer surface of the skin was lost after two to three days, followed 281 
subsequently by corneal flaking which resolved in 5 days. The lesions were initially slightly 282 
painful to touch and were treated with wet cold towels, dried and followed by an ointment 283 
containing methyl salicylate, Peru balsam (exudation of Myroxilon peruiferum) and zinc 284 
oxide (Balsamex; Chemitec Agro-Veterinária Ltda, SP, Brazil). These injured local sites were 285 
not used again for further thermal stimulation for the remaining treatments.  286 
 287 
Discussion  288 
Detomidine (10 µg kg-1) with methadone produced the most intense and prolonged 289 
antinociception. When the detomidine dose was reduced to 5 µg kg-1, antinociception was of 290 
similar intensity but of shorter duration, the horses were less sedated and intestinal motility 291 
better preserved. This observation confirms that methadone potentiates detomidine-induced 292 
antinociception, not only at the high detomidine dose of 10 µg kg-1 (Oliveira et al. 2014; 293 
Lopes et al. 2016), but also at 5 µg kg-1, while sedative effects are minimized. Moreover, the 294 
lowest dose of detomidine (2.5 µg kg-1) combined with methadone produced antinociception 295 
similar to that after detomidine alone (5 µg kg-1), yet without producing measurable sedation. 296 
No conclusion as to potentiation can be drawn regarding this combination as treatment with 297 
detomidine alone at 2.5 µg kg-1 was not studied. 298 
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Nociceptive electrical, thermal and mechanical stimulation on the thoracic limbs is 299 
easy to apply and interpret, is reliable, sensitive and specific, and has been validated in horses 300 
(Luna et al. 2015). Electrical stimuli activate not only the nociceptive Aδ and C fibres, but 301 
also large diameter Aβ fibres not directly involved in antinociception (Le Bars et al. 2001). 302 
Thermal stimulation with a slow heating rate of 0.8 °C second-1 predominantly activates C 303 
fibres (Yeomans & Proudfit 1996; Lopes et al. 2016) and mechanical stimuli activate both 304 
nociceptive Aδ and C fibres (Le Bars et al. 2001). Since opioids and α2-agonists have 305 
different mechanisms of action, the use of a variety of nociceptive stimuli improves 306 
sensitivity and specificity and therefore produces more accurate data (Luna et al. 2015; Lopes 307 
et al. 2016). All three nociceptive testing modalities were sufficiently sensitive to detect 308 
different degrees of antinociception between treatments, and, in general, followed a similar 309 
trend.  310 
The equipment employed for application of nociceptive stimuli was the same as 311 
previously reported (Luna et al. 2015; Lopes et al. 2016). Additional features were included 312 
for the electrical stimulus: before application, a strict protocol of clipping, washing, 313 
degreasing and cleaning was followed. Since current intensity is equal to voltage divided by 314 
resistance (Ohm´s law), increases in skin resistance reduce intensity. Studies where resistance 315 
was not measured showed heterogeneous, less accurate data (Lopes et al. 2016). Thus, proper 316 
control of resistance is mandatory, not only by preparing the area and maintaining the same 317 
distance between electrodes (7-8 cm on the coronary band), but also by keeping resistance 318 
values below 3 kΩ (Hopster et al. 2014; Risberg et al. 2014). 319 
The drug doses used in this study were chosen to identify a combination that would 320 
produce adequate antinociception with minimal adverse effects. Detomidine (10-20 µg kg-1) 321 
and methadone (0.1-0.2 mg kg-1) are commonly used clinical doses. In the present study, 322 
methadone alone (0.2 mg kg-1) administered IV resulted in only transitory, minor behavioral 323 
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effects and no antinociception. Similar results were reported by Oliveira et al. (2014), where 324 
mild ataxia and head shaking were observed for 30 minutes, without consistent 325 
antinociception. However, the addition of methadone (0.2 mg kg-1) to detomidine (5 µg kg-1) 326 
as described here, and to 10 µg kg-1 as reported by Oliveira et al. (2014) and Lopes et al. 327 
(2016), prolonged the detomidine-induced antinociception and abated the methadone-induced 328 
behavioral effects. Combination with detomidine (2.5 µg kg-1) also appeared to reduce the 329 
adverse effects of methadone, resulting in minimal adverse reactions in only two of the 330 
horses. 331 
Antinociception was observed in all treatments that included detomidine. In general, 332 
thresholds followed a similar pattern in the two treatments DET and MLD and in MMD and 333 
MHD, with longer durations of antinociception when methadone was combined with 5 or 10 334 
µg kg-1 detomidine. The results indicate that the combination of methadone (0.2 mg kg-1) 335 
with detomidine (5 µg kg-1) could provide useful antinociceptive effects for some clinical 336 
procedures lasting around 30 minutes.  337 
Excessively deep sedation and severe ataxia may be considered adverse effects under 338 
clinical conditions. In the study presented here, a reduction in the detomidine dose from 10 in 339 
MHD to 5 µg kg-1 in MMD resulted in a similar degree of antinociception, but less sedation 340 
(HHAG). Sedation in DET (5 µg kg-1) was comparable to MHD, but of shorter duration. The 341 
lowest detomidine dose combined with methadone (MLD) produced similar antinociception 342 
to detomidine alone (DET), without apparent sedation. The HHAG variable has been used to 343 
measure the degree of sedation induced by administration of α2-agonists. Previous authors 344 
have defined ‘sufficient’ sedation as when the horse’s head position is equal to or lower than 345 
50% of the awake position (Ringer et al. 2012; Marly et al. 2014). Using this definition, 346 
adequate sedation was achieved only at 15 minutes after detomidine alone and for 30 minutes 347 
in MHD, whereas sufficient sedation was not achieved with the other treatments. However, 348 
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the term ‘sufficient’ should be used carefully when an opioid is added to low doses of α2-349 
agonists, as opioid-linked behavioral effects may overcome the sedative effects of the α2-350 
agonist, depending on the relative dose ratio of the drugs.  351 
Contrary to HHAG, VAS was similar in DET, MHD and MMD for the first 30 352 
minutes. Moreover, the VAS detected more differences in sedation quality than the NRS used 353 
to score ataxia and responses to tactile and audiovisual stimuli. As two of these three tactile 354 
stimuli were performed on the limbs, it might be expected that methadone would increase 355 
locomotor activity (Oliveira et al. 2014) and, potentially increase the bias of these responses. 356 
However, the significant ataxia seen in treatments with detomidine at doses equal to or higher 357 
than 5 µg kg-1 may have reduced the responses to the tactile stimuli..  358 
Throughout the experiments, the values for HR, SAP and fR remained within 359 
clinically acceptable ranges. As reported by Wagner et al. (1991) with a detomidine dose of 360 
10 µg kg-1, initial increases in arterial pressure, followed by a decrease, was observed only 361 
with the combinations including the highest dose of detomidine. Reducing this dose limited 362 
the biphasic effect on arterial pressure. fR decreased below baseline for 60 minutes only in 363 
MHD, but this was not statistically different from the other treatments. It is possible that 364 
detomidine and its combination with methadone may cause respiratory depression, especially 365 
at the highest dose, but arterial blood gases were not measured in this study.  366 
Invasive arterial pressure measurements would have produced more accurate 367 
measurements. However, a noninvasive method was used because evaluation of the 368 
cardiopulmonary effects of the treatments was not the main aim of the study, and arterial 369 
catheterization may have stimulated the horses and affected subsequent sedation and 370 
antinociception.   371 
Duration and intensity of intestinal hypomotility was detomidine dose-dependent. The 372 
reduction in intestinal motility and its possible consequences are well reported after both α2-373 
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agonists (Daunt & Steffey 2002; Valverde 2010) and opioids (Bennett & Steffey 2002; 374 
Boscan et al. 2006; Clutton 2010; Schauvliege 2014).  375 
One horse developed small lesions at the site of thermal stimulation. Development of 376 
skin lesions was unexpected as the cut-out was set at 60 °C, based on previous similar 377 
studies, where only occasional superficial, local lesions were seen, usually at a thoracic site 378 
and not on the limbs (Luna et al. 2015). A 60 °C cut-out may not be suitable for all conditions 379 
as some individuals may be more sensitive to thermal stimulation. A lower cut-out such as 55 380 
°C might be appropriate for different environments, sites and breeds to avoid tissue damage. 381 
This horse became deeply sedated after all treatments, which may have influenced the results. 382 
However, its exclusion would not be justified as this horse could represent a real effect seen 383 
in a certain proportion of the population. It is also possible that allodynia developed after the 384 
thermal injury in this horse, changing responses in subsequent experiments. Nonetheless, 385 
separate statistical analysis performed without this horse´s data did not significantly modify 386 
the nociceptive results.  387 
  388 
Conclusions 389 
Methadone (0.2 mg kg-1) potentiated the antinociception produced by detomidine at 5 µg kg-390 
1
. However, side effects such as deep sedation, ataxia and prolonged intestinal hypomotiliy 391 
were diminished when methadone was combined with 5 µg kg-1 detomidine when compared 392 
with the combination with 10 µg kg-1 detomidine. Further studies are justified to evaluate the 393 
value of this combination  under clinical conditions. 394 
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Appendix A Numerical rating scale (NRS) to assess ataxia and responses to tactile and audiovisual stimulation. Adapted from Bryant et al. 482 
(1991) and Ringer et al. (2013). 483 
NRS 
Degree of ataxia Tactile stimuli Audiovisual stimuli 
Evaluated visually and by 
pushing the horse to detect any 
swaying 
 
 
Touching an ear with a pen, then pressing 
the coronary band of thoracic and pelvic 
limbs with the pen 
Acoustic stimulus was hand clapping 
behind the horse and visual stimulus was 
shaking a towel in front of the horse 
0 
 
 
No ataxia 
 
 
No response, even with strong pressing No response, no signs of noise recognition 
or visual arousal 
 
1 
 
 
Stable but swaying slightly 
 
 
Mild response, slightly diminished response 
to normal or strong pressing 
Mild response, minimal movement of ears 
and elevates head slightly 
 
2 
 
Unstable, swaying markedly 
 
Intermediate response, animal elevates the 
limb after normal pressing 
Intermediate response, subdued reactions 
and movements, turning slowly 
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3 
 
Severe ataxia, risk of falling down 
 
Fast response, movement of the limb after 
touching, with mild pressing 
Fast response, animal abruptly turns or 
moves away  
 484 
  485 
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Appendix B Scoring of intestinal sounds (Boscan et al. 2006).  486 
 487 
 488 
 489 
  490 
Score Criteria 
0 No intestinal sounds auscultated 
1 Low-pitched crepitant sounds, frequency ≤ 1 minute-1 
2 Low-pitched crepitant sounds, frequency > 1 minute-1 
3 Long, loud, gurgling sounds, frequency 1 minute-1 
4 Long, loud, gurgling sounds, frequency 2 to 4 minute-1 
5 Long, loud, gurgling sounds, frequency > 4 minute-1 
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Table 1 Sedation quality evaluated by visual analogue scale (VAS) [median (range)]. 0 indicates no sedation and no ataxia and 10 indicates maximum 491 
sedation and ataxia, in eight standing horses after six treatments administered intravenously: 10 mL saline (SAL), 5 µg kg-1 detomidine (DET), 0.2 mg 492 
kg-1 methadone alone (MET), or combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg kg-1 detomidine before (time 0) and after (times 5-180 493 
minutes) drug administration.  494 
Time 
(minutes)  
Treatment 
SAL MET DET MLD MMD MHD 
0 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 
5 0 (0 - 0)
a
 0 (0 - 1.3)a 5.3 (2.1 - 6.4)*abc 0 (0 - 8.7)ab 6.3 (4.9 - 8.8)*bc  7.8 (6.4 -9.9)*c 
15 0 (0 - 0)
a
 0 (0 - 0.9)ab 6.2 (2.9 - 7.5)*bcd 0 (0 - 8.9)abc 6.2 (4.0 - 8.1)*cd 9.1 (6.1 - 9.6)*d 
30 0 (0 - 0)
a
 0 (0 - 0)a 4.6 (0 - 6.4)*abc 0 (0 - 7.1)ab 3.3 (1.4 - 7.9)*bc 6.7 (3.9 - 8.6)*c 
45 0 (0 - 0)
a
 0 (0 - 0)a 1.0 (0 - 4.5)ab 0 (0 - 4.5)a 0.5 (0 - 6.2)ab 3.4 (1.3 - 7.8)b 
60 0 (0 - 0)
a
 0 (0 - 0)a 0 (0 - 1.4)ab 0 (0 - 1.7)ab 0 (0 - 2.2)ab 1.4 (0 - 5.2)b 
75 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 3) 
90 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 2.1) 
120 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 
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180 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 
 495 
*Significantly different from baseline (time 0) (p < 0.05). abcDifferent superscript letters indicate significant differences among treatments at that time 496 
point (p < 0.05).  497 
 498 
  499 
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Table 2 Heart rate (HR), systolic arterial blood pressure (SAP) and respiratory rate (fR) (mean ± standard deviation) in eight standing horses 500 
administered intravenous saline (SAL), 5 µg kg-1 detomidine (DET), 0.2 mg kg-1 methadone alone (MET), or combined with 10 (MHD), 5 (MMD) or 501 
2.5 (MLD) µg kg-1 detomidine.  502 
Variable  
Time  
(minutes) 
Treatments 
SAL 
 
MET 
 
DET 
 
MLD 
 
MMD 
 
MHD 
 
HR  
(beats minute-1) 0 37 ± 11a 32 ± 4b 34 ± 6bc 36 ± 6a 33 ± 5ac 35 ± 5b 
 
5 37 ± 14a   33 ± 5b 30 ± 5bc 36 ± 10a 33 ± 8ac 29 ± 5b 
 
15 37 ± 12a 35 ± 3b 34 ± 10bc 36 ± 9a 35 ± 8ac 31 ± 5b 
 
30 38 ± 13a 31 ± 4b 34 ± 8bc 38 ± 11a 35 ± 7ac 30 ± 5b 
 
45 35 ± 12a 31 ± 3b 35 ± 7bc 38 ± 12a 35 ± 7ac 31 ± 4b 
 
60 37 ± 12a 33 ± 4b 33 ± 6bc 34 ± 6a 35 ± 9ac 32 ± 4b 
 
75 37 ± 13a 33 ± 3b 34 ± 7bc 37 ± 11a  37 ± 9ac 32 ± 5b 
 
90 38 ± 13a 32 ± 4b 32 ± 6bc 36 ± 6a 40 ± 8ac 33 ± 4b 
 
120 37 ± 12a 31 ± 3b 36 ± 8bc 37 ± 10a 35 ± 7ac 33 ± 5b 
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180 37 ± 12a 32 ± 3b 33 ± 6bc 38 ± 12a 37 ± 8ac 33 ± 4b 
SAP (mmHg) 0 139 ± 15 161 ± 11 143 ± 12 122 ± 9 125 ± 6 127 ± 6 
 5 133 ± 9a 143 ± 13a 149 ± 16a 148 ± 11a 148 ± 8a 193 ± 13*b 
 15 153 ± 22ab 156 ± 22a 110 ± 6*c 137 ± 12abc 127 ± 11bc 138 ± 7ab 
 30 154 ± 11ab 165 ± 5a 149 ± 7ab 131 ± 10b 141 ± 15ab 134 ± 13b 
 45 132 ± 12 130 ± 4* 141 ± 6 143 ± 8 144 ± 7 138 ± 4 
 60 168 ± 10*a 136 ± 29bc 151 ± 41ab 137 ± 5bc 114 ± 5c 143 ± 17ab 
 75 134 ± 6a 131 ± 4*b 143 ± 25ab 126 ± 21a 143 ± 11ab 168 ± 9*b 
 90 141 ± 23 145 ± 13 126 ± 6 137 ± 12 140 ± 12 132 ± 7 
 120 141 ± 13 127 ± 11* 133 ± 25 127 ± 8 124 ± 9 138 ± 21 
 180 127 ± 6ab 126 ± 4ab 116 ± 9a 149 ± 7b 139 ± 7ab 123 ± 8ab 
fR 
(breaths minute-1) 0 16 ± 4 16 ± 4 16 ± 4 15 ± 3 15 ± 2 17 ± 5 
 5 16 ± 4a 16 ± 6ab 10 ± 2ab 12 ± 6ab 10 ± 3ab 8 ± 2*b 
 15 16 ± 3a 17 ± 7b 10 ± 2ab 13 ± 6ab 9 ± 2ab 8 ± 1*b 
 30 16 ± 4ab 19 ± 6a 10 ± 2bc 13 ± 5abc 9 ± 2bc 8 ±1*c 
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 45 17 ± 4ab 18 ± 6a 11 ± 2bc 14 ± 6abc 11 ± 3bc 10 ± 2*c 
 60 17 ± 4ab 19 ± 7a 11 ± 2b 14 ± 6ab  12 ± 2b 10 ± 2*b 
 75 17 ± 5 18 ± 7 12 ± 2 15 ± 4 12 ± 3 11 ± 1 
 90 17 ± 4 18 ± 6 13 ± 2 15 ± 5 14 ± 2 12 ± 2 
 120 18 ± 4 18 ± 5 14 ± 3 15 ± 3 14 ± 2 12 ± 2 
 180 18 ± 4 18 ± 5 14 ± 2 15 ± 3 15 ± 2 13 ± 2 
*Significantly different from baseline (time 0) within a treatment (p < 0.05).  503 
abcDifferent superscript letters indicate significant differences among treatments at that time point (p < 0.05).  504 
 505 
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Table 3 Electrical (upper safety limit 20 V), thermal (upper safety limit 60 °C) and mechanical (upper safety limit 20 N) thresholds in eight 507 
standing horses treated intravenously with 10 mL saline (SAL), 5 µg kg-1 detomidine (DET), 0.2 mg kg-1 methadone (MET), or methadone 508 
combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg kg-1 detomidine. Thermal threshold data are mean ± standard deviation; electrical and 509 
mechanical threshold data are geometric means (back-transformed bounds of the 95% confidence interval).  510 
 511 
Stimulus 
 
Time 
(minutes) 
Treatment 
SAL MET DET MLD MMD MHD 
Electrical (V) 0 1.7 (1.5, 2.1) 1.6 (1.3, 1.8) 1.4 (1.2, 1.7) 1.7 (1.4, 2.0) 1.7 (1.4, 2.0) 1.8 (1.5, 2.2) 
 5 1.7 (1.4, 2.1)a 1.7 (1.3, 2.2)a 2.9 (2.0, 4.1)*ab 3.0 (1.5, 6.1)*ab 4.7 (3.4, 6.6)*bc 6.1 (3.4, 10.9)*c 
 15 1.9 (1.6, 2.3)a 1.9 (1.5, 2.4)a 3.1 (2.2, 4.4)*ab 2.8 (1.8, 4.5)ab 4.0 (2.7, 5.9)*b 8.4 (6.0, 11.7)*c 
 30 1.9 (1.6, 2.3)a 1.7 (1.4, 2.0)a 1.8 (1.5, 2.2)a 2.4 (1.6, 3.6)a 2.9 (1.9, 4.5)a 6.2 (3.6, 10.8)*b 
 45 1.7 (1.3, 2.2)ab 1.7 (1.4, 2.0)a 1.8 (1.4, 2.3)ab 2.0 (1.4, 2.9)ab 2.3 (1.6, 3.2)ab 3.0 (2.7, 3.4)b 
Thermal (°C) 0 44 ± 4 44 ± 3 44 ± 3 44 ± 3  44 ± 4 44 ± 2 
 5 44 ± 5a 44 ± 3a 54 ± 5*b 53 ± 6*b 59 ± 2*b 60 ± 0*b 
 15 43 ± 3a 47 ± 6ab 51 ± 5*bc 52 ± 7*bc 56 ± 5*cd 60 ± 0*d 
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 30 44 ± 4a 44 ± 5a 45 ± 2a 49 ± 5ab 52 ± 6*b 60 ± 1*c 
 45 42 ± 4a 44 ± 4a 45 ± 3a  45 ± 3a 49 ± 5ab 55 ± 5*b 
Mechanical 
(N) 0 1.1 (0.6, 2.2)   0.9 (0.6, 1.3)   0.9 (0.6, 1.2)   0.8 (0.6, 1.2)   1.0 (0.6, 1.7)   0.9 (0.5, 1.5)  
 5 1.8 (0.9, 3.5)a 1.5 (0.5, 4.0)a 4.4 (2.1, 9.5)*ab 4.7 (1.8, 12.0)*ab 17.4 (12.9, 20.0†)*b 20.0 (20.0, 20.0)*b 
 15 1.3 (0.7, 2.6)a 1.6 (0.6, 4.0)a 2.5 (0.9, 6.7)a 4.8 (2.0, 11.4)*ab 15.1 (9.9, 20.0†)*b 20.0 (20.0, 20.0)*b 
 30 1.5 (0.8, 2.9)a 1.7 (0.7, 4.0)a 2.4 (1.4, 4.0)a 3.1 (1.2, 7.9)a 6.5 (2.0, 20.0†)*ab 19.2 (17.4, 20.0†)*b 
 45 1.5 (0.8, 2.7)a 1.5 (0.6, 3.4)a 1.4 (0.9, 2.2)a 3.2 (1.2, 8.1)ab 3.8 (1.6, 8.7)ab 13.1 (8.7, 19.7)*b 
 60 1.3 (0.8, 2.2)a 1.7 (0.9, 3.2)ab 1.2 (0.7, 2.1)a 1.5 (0.8, 2.8)ab 1.9 (0.8, 4.5)ab 6.4 (3.2, 12.6)*b 
*Significantly increased above baseline (time 0) (p < 0.05). Different lower case letters at each time point for each variable indicate significant 512 
differences among treatments (p < 0.05).  513 
†Indicates that the upper limit of the confidence interval was higher than 20, although mechanical thresholds were censored at 20N. 514 
 515 
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Figure legends 517 
 518 
Figure 1 Height of head above the ground (HHAG) in eight standing horses administered 519 
intravenously saline (SAL), 5 µg kg-1 detomidine (DET), 0.2 mg kg-1 methadone alone 520 
(MET), or combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg kg-1 detomidine. Data are 521 
mean ± standard deviation.  522 
*Significantly lower from time 0 and lower than MET (p < 0.05). 523 
†Significantly lower from time 0 and lower than SAL, MET and MLD (p < 0.05). 524 
‡Significantly lower from time 0 and lower than SAL, MET, MLD and MMD (p < 0.05).  525 
 526 
 527 
Figure 2 Intestinal motility scores (mean ± standard deviation) in eight standing horses 528 
administered intravenously saline (SAL), 5 µg kg-1 detomidine (DET), 0.2 mg kg-1 529 
methadone alone (MET), or combined with 10 (MHD), 5 (MMD) or 2.5 (MLD) µg kg-1 530 
detomidine.  531 
*Significantly lower from time 0 (p < 0.05). †Significantly higher than all other treatments (p 532 
< 0.05). ‡Significantly higher than MHD (p < 0.05). §Significantly lower than MET, DET, 533 
MLD, MMD (p < 0.05). ¶Significantly lower than DET and MLD (p < 0.05). 534 
 535 
 536 
 537 
 538 
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